title: Optic neuropathy in methylmalonic acidemia: the role of neuroprotection.
abstract: We report the case of a patient with an optic neuropathy induced by neurotoxicity in the setting of methylmalonic acidemia. The patient responded with a significant and long-term improvement in visual acuity, perimetry, and chromatic function after a neuroprotective treatment with vitamin E and coenzyme Q10 was started. Coenzyme Q10 levels had been proven to be normal before starting treatment. This case report is particularly important because it describes a possible treatment for optic neuropathy in methylmalonic patients. Although the response might be, in part, specific to the individual, it suggests the existence of a cause-effect relationship between the treatment undergone by our patient and the improvement in her visual acuity. To date, no other treatments with beneficial effects have been reported for the few optic neuropathies caused by methylmalonic acidemia. Further studies should determine the applicability of coenzyme Q10 and vitamin E for the treatment of optic neuropathies in methylmalonic acidemia.
authors.affiliation: Department of Ophthalmology, Hospital de Cruces, Plaza de Cruces, 48903 Barakaldo, Vizcaya, Spain. luengonosvemos@yahoo.es
authors.forename: Sergio
authors.initials: S
authors.lastname: Pinar-Sueiro
authors.forename: Ricardo
authors.initials: R
authors.lastname: Martínez-Fernández
authors.forename: Sergio
authors.initials: S
authors.lastname: Lage-Medina
authors.forename: Luis
authors.initials: L
authors.lastname: Aldamiz-Echevarria
authors.forename: Elena
authors.initials: E
authors.lastname: Vecino
mesh_terms: D000293:Adolescent; D000592:Amino Acid Metabolism, Inborn Errors / Q000150:complications* / Q000175:diagnosis / Q000178:diet therapy / Q000235:genetics; D000975:Antioxidants / Q000627:therapeutic use; D002478:Cells, Cultured; D004252:DNA Mutational Analysis; D018753:Diet, Protein-Restricted; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use; D009901:Optic Nerve Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D020127:Recovery of Function; D013997:Time Factors; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000627:therapeutic use; D014792:Visual Acuity; D014810:Vitamin E / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D018696:Neuroprotective Agents; D014451:Ubiquinone; D014810:Vitamin E; C024989:coenzyme Q10
references.citation: Pediatr Res. 2009 Jul;66(1):91-5
references.pmid: 19342984
references.citation: Int Rev Neurobiol. 2007;82:397-406
references.pmid: 17678974
references.citation: J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):281-7
references.pmid: 16763889
references.citation: Am J Ophthalmol. 2009 May;147(5):929-33
references.pmid: 19243738
references.citation: Prog Brain Res. 2008;173:575-82
references.pmid: 18929135
references.citation: Neuroreport. 2000 Feb 28;11(3):541-4
references.pmid: 10718311
references.citation: Ophthalmic Genet. 2000 Sep;21(3):151-4
references.pmid: 11035547
references.citation: J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):423-5
references.pmid: 11909893
references.citation: Exp Neurol. 2006 Sep;201(1):165-71
references.pmid: 16740260
references.citation: J Inherit Metab Dis. 2009 Aug;32(4):570-5
references.pmid: 19504350
references.citation: Ann Neurol. 1993 Jan;33(1):103-4
references.pmid: 8494328
references.citation: Pediatr Neurol. 2006 Feb;34(2):156-9
references.pmid: 16458832
references.citation: Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):104-12
references.pmid: 16602092